These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 18508813)

  • 1. Pharmaceutical reform in South Korea and the lessons it provides.
    Kim HJ; Ruger JP
    Health Aff (Millwood); 2008; 27(4):w260-9. PubMed ID: 18508813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons from Korea's pharmaceutical policy reform: the separation of medical institutions and pharmacies for outpatient care.
    Kim HJ; Chung W; Lee SG
    Health Policy; 2004 Jun; 68(3):267-75. PubMed ID: 15113638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
    Yang BM; Bae EY; Kim J
    Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
    Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Korea's National Health Insurance--lessons from the past three decades.
    Jeong HS
    Health Aff (Millwood); 2011 Jan; 30(1):136-44. PubMed ID: 21209449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
    Schwermann T; Greiner W; v d Schulenburg JM
    Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan.
    Lee YC; Huang KH; Huang YT
    Health Policy Plan; 2007 Nov; 22(6):427-35. PubMed ID: 17901065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incentives and pharmaceutical reimbursement reforms in Spain.
    Puig-Junoy J
    Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997-2006.
    Martin BI; Turner JA; Mirza SK; Lee MJ; Comstock BA; Deyo RA
    Spine (Phila Pa 1976); 2009 Sep; 34(19):2077-84. PubMed ID: 19675510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reform of the health care service system in Israel 1995-2000.
    Hart J
    World Hosp Health Serv; 2001; 37(3):9-11, 40, 42. PubMed ID: 11858011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interest groups' influence over drug pricing policy reform in South Korea.
    Chung WJ; Kim HJ
    Yonsei Med J; 2005 Jun; 46(3):321-30. PubMed ID: 15988802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The changing process and politics of health policy in Korea.
    Kwon S; Reich MR
    J Health Polit Policy Law; 2005 Dec; 30(6):1003-26. PubMed ID: 16481306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A DID analysis of the impact of health insurance reform in the city of Hangzhou.
    Zhang J
    Health Econ; 2007 Dec; 16(12):1389-402. PubMed ID: 17351883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from the first to the latest nation to enact national health insurance.
    Eastaugh SR
    J Am Health Policy; 1992; 2(6):32-4. PubMed ID: 10122416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National health spending projections: the estimated impact of reform through 2019.
    Sisko AM; Truffer CJ; Keehan SP; Poisal JA; Clemens MK; Madison AJ
    Health Aff (Millwood); 2010 Oct; 29(10):1933-41. PubMed ID: 20829295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Key concepts for modernization of the health care system].
    Bundesministerium für Gesundheit und Soziale Sicherung, Berlin
    Urologe A; 2003 Apr; 42(4):469-70. PubMed ID: 12715119
    [No Abstract]   [Full Text] [Related]  

  • 17. [Quality assurance: MDS (Medical Services of Key Alliances of National Health Insurance) favors greater involvement of national health insurance].
    Martmann-Sprenger S
    Gesundheitswesen; 2003 May; 65(5):343. PubMed ID: 12841220
    [No Abstract]   [Full Text] [Related]  

  • 18. Entry of new pharmacies in the deregulated Norwegian pharmaceuticals market--consequences for costs and availability.
    Rudholm N
    Health Policy; 2008 Aug; 87(2):258-63. PubMed ID: 18164509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
    Suh HS; Kim JA; Lee IH
    BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.